08:13 AM EDT, 10/15/2024 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) said Tuesday that it has received "positive" preliminary results from its late-stage clinical trial of Zepzelca in combination with atezolizumab as a maintenance treatment for adults with extensive-stage small cell lung cancer, or ES-SCLC, following induction therapy with carboplatin, etoposide, and atezolizumab.

The company said the combination showed "a statistically significant improvement" in primary endpoints of overall survival and progression-free survival when compared to treatment with atezolizumab alone.

Jazz said it plans to file a supplemental New Drug Application for the combination therapy as a first-line maintenance treatment for ES-SCLC in the first half of next year.

Price: 111.78, Change: +0.75, Percent Change: +0.68